Most of our readers will be familiar with the idea that progression of prostate cancer over time is associated with the expression of androgen receptors (ARs) in prostate cancer tissue. Once prostate cancer leaves the prostate and starts the process of metastasis, standard forms of androgen deprivation therapy like LHRH agonists, antiandrogens, and other agents […]![]()
